Local treatment of metastases such as metastasectomy or radiotherapy remains controversial in the treatment of metastatic renal cell carcinoma. To investigate the benefi ts and harms of various local treatments, we did a systematic review of all types of comparative studies on local treatment of metastases from renal cell carcinoma in any organ. Interventions included metastasectomy, radiotherapy modalities, and no local treatment. The results suggest that patients treated with complete metastasectomy have better survival and symptom control (including pain relief in bone metastases) than those treated with either incomplete or no metastasectomy. Nevertheless, the available evidence was marred by high risks of bias and confounding across all studies. Although the fi ndings presented here should be interpreted with caution, they and the identifi ed gaps in knowledge should provide guidance for clinicians and researchers, and directions for further research.
Introduction
Renal cell carcinoma frequently leads to synchronous or metachronous metastases 1, 2 and has an estimated agestandardised mortality in Europe of 2·6%. 3 For synchronous metastatic renal cell carcinoma, cyto reductive nephrectomy in combination with treatment with interferon alfa resulted in a signifi cant improve ment in median overall survival compared with treatment with interferon alfa alone. 4 However, in the era of targeted treatment the role of cytoreductive nephrectomy is not well defi ned. With present targeted drugs, the proportion of patients achieving an objective response has been between 20-40%, but complete responses were reported in only 1-3% of patients. [5] [6] [7] Data from a population-based analysis suggest that median overall survival plateaus at 9-40 months, depending on patients' clinical risk scores. 8 Therefore, with the exception of rare but durable responses after high-dose interleukin 2, removal of all synchronous or metachronous lesions, when technically feasible and clinically appropriate, provides the only potentially curative treatment alternative. However, the benefi ts of local therapeutic options for metastases from renal cell carcinoma are controversial. Despite retrospective data suggesting consistently that complete resection of solitary or oligometastatic metastatic renal cell carcinoma suggests a favourable prognosis independent of race or geographical location, 9 uncertainty exists as to whether this is because of favourable tumour biology, the role of metastasectomy, or both. Less disputed benefi ts of complete resection include symptom palliation, and delay or withdrawal of systemic treatment, thereby avoiding associated toxicities.
Metastases from renal cell carcinoma are common in lung, bone, liver, and brain, but can occur at any anatomical site. 10, 11 Surgical resection is a possible treatment for these metastases, but metastases' accessibility and resectability, and patients' performance and comorbidities have to be taken into account. 12 Radiotherapy modalities can provide valid local noninvasive treatment alternatives to surgery. For brain metastases, these include whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS). By contrast with WBRT, SRS delivers highly collimated radiation to a precisely defi ned target area, minimising the radiation dose to surrounding areas. 13 For other sites, including bone, conventional radiotherapy (CRT) or stereotactic body radiotherapy (SBRT) are options. CRT is fractionated radiotherapy primarily applied to treat painful metastases, whereas SBRT, like SRS, delivers high-dose single-fraction or multi-fraction radiation. 14 Until now, no systematic review on the outcome of diff erent local treatment options for metastases from renal cell carcinoma has been done, and there is a need to identify potential benefi ts of such an approach. Therefore, in this systematic review, we aimed to address the question of whether integration of local treatment of metastases into the management of metastatic renal cell carcinoma is benefi cial and, if so, what the best treatment modalities are.
Search strategy and selection criteria
The review was done according to Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines, 15 and in accordance with the principles outlined in the Cochrane Handbook for Systematic Reviews of Interventions. 16 Studies were identifi ed by searching electronic databases and relevant websites. Sensitive electronic searches were done to identify reports of randomised controlled trials or nonrandomised comparative studies of local treatment for metastatic renal cell carcinoma. The search strategy excluded studies published before Jan 1, 2000, and there were no language restrictions. We searched Medline (January, 1946 , to Sept 30, 2013) , Medline In-Process (from inception up to Sept 30, 2013) , Embase (January, 1974 , to Sept 30, 2013) , Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 8, 2013) , and Latin American and Caribbean Center on Health Sciences Information (from January 1967, to Sept 30, 2013) . Additional reports were identifi ed through searches of the reference lists of included studies and by Only comparative studies were included, including randomised controlled trials, prospective non-randomised comparative interventional studies, prospective observational studies with a comparator arm, and retro spective comparative studies. Studies with no comparator group (eg, single-arm case series), non-eff ectiveness studies (eg, prognostication or nomogram studies), reviews, or studies with fewer than ten patients per group were excluded, as were reviews, basic science studies, genetic or epidemiological studies, case series or case reports, studies of local recurrence only, studies of tumour thrombosis of the vena cava, studies of experi mental treatments, studies of systemic treatment only, and studies examining only localised treatments for primary kidney cancer. Some of these excluded studies were retained for discussion, to give clinical context as to the relevance and implication of the review fi ndings.
The patient population assessed included patients with metastatic renal cell carcinoma to any organ, except those with synchronous metastases to the ipsilateral adrenal gland or retroperitoneal lymph nodes only. There were no restrictions regarding previous treatment with cytoreductive nephrectomy or systemic or targeted treatment. The types of interventions included metastasectomy with or without intended complete resection of metastases in any organ, WBRT, CRT, SRS, SBRT, CyberKnife radiotherapy, hypofractionated radiotherapy, and no local treatment. The primary outcomes assessed were overall survival, cancer-specifi c survival, and progression-free survival. Local tumour control, quality of life, symptom control, and adverse events or toxic eff ects were assessed as secondary outcomes.
Two reviewers (SD and LM) independently screened titles and abstracts of all references identifi ed by the search strategies. Full text copies of all potentially relevant reports were obtained and independently assessed by two reviewers (SD and LM) to identify whether they met the predefi ned inclusion criteria. Any disagreements were resolved by consensus or arbitration by a third person (TBLL). A data extraction form was developed specifi cally for the purpose of this assessment to collect information on study design, characteristics of participants, character istics of interventions, and outcome measures. Two reviewers (SD and LM) independently assessed the risk of bias of individual studies. The standard Cochrane Collaboration risk of bias instrument 16 was used to assess the risk of bias in randomised controlled trials, whereas for non-randomised comparative studies the risk of bias instrument recommended by the Cochrane Non-Randomised Studies Methods Group was used. 16 Additionally, for non-randomised comparative studies, the main confounders for the primary outcomes (ie, survival or tumour response) were identifi ed a priori by the expert panel. The main confounders identifi ed were age, sex, Fuhrman grade, size or volume of metastases, previous treatment before local treatment, performance status, treatment of diff erent sites in the same study, and tumour histology. The confounders were assessed for the following four criteria: fi rst, whether the confounder was considered by the study author; second, the precision of measurement; third, if there was a baseline imbalance between the intervention and comparator group or groups; and fi nally, the quality of adjustment for imbalance in studies with various treatment sites. 18 A study was regarded as at high risk of bias, if any of the confounders were imbalanced between experimental groups. For outcomes in which the data synthesis involved randomised control trials, or nonrandomised comparative studies with low risk of bias, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) 19 was used to assess the quality of evidence.
For data analysis, descriptive statistics were used to summarise baseline characteristics. A quantitative synthesis (ie, meta-analysis) was planned for randomised controlled trials only, because of the inherent clinical and methodological heterogeneity present in non-randomised studies. When pooling of data was not done, and where appropriate, results were presented in forest plots to allow a visual comparison of the eff ects of interventions between studies. Both fi xedeff ects and random-eff ects models were used to derive 20 In analysing dichotomous outcomes, relative risks with 95% CIs were used, whereas for continuous outcomes, means and SDs or medians and ranges were used to summarise the data, and weighted mean diff erences and 95% CIs were used to compare interventions. Statistical heterogeneity between studies was assessed by visual inspection of plots of the data, the χ² test for heterogeneity, and the I² statistic. 21 Analyses were done using Cochrane RevMan version 5.2. If a meta-analysis was not feasible, a narrative synthesis was provided. 
Review Findings
The literature search identifi ed 2180 studies, 189 of which were selected for full-text screening (fi gure 1). Six articles in languages other than English were translated. 16 studies reporting on 2350 patients were eligible for fi nal inclusion. Of studies not meeting the inclusion criteria, 34 were retained for discussion. All 16 included studies were retrospective comparative studies (table 1) . No randomised controlled trials or prospective non-randomised comparative studies were identifi ed. Eight studies assessed local treatments of metastases from renal cell carcinoma in various organs, 12, 24, 26, 27, [29] [30] [31] [32] of which the most common sites were lung, bone, liver, and brain, and less common sites were pancreas, adrenal gland, lymph nodes, thyroid gland, spleen, ethmoid sinus, and skin (table 1) . Other studies also assessed local treatments for metastases from renal cell carcinoma in bone (including the vertebrae), 33 Review pancreas (table 1) . 28 Three studies 23, 24, 26 were abstracts only (table 1). The heterogeneity of data did not allow for a metaanalysis; a narrative synthesis of the evidence is presented instead. There was great variation in the type and distribution of systemic treatments and in their reporting across studies. Generally, systemic treatment consisted of cytokines and VEGF inhibitors. Eight studies 23, 26, 27, 31, 33, 34, 36, 37 contained no information on whether systemic treatment was given; three studies 12, 24, 35 did not specify the type of systemic treatment. Three studies 25, 28, 32 used treatment after metastasectomy and one study 29 used treatment beforehand. In one study, 30 systemic treatment was not used.
Complete versus no or incomplete metastasectomy
All of the eight studies 12, 24, 26, 27, [29] [30] [31] [32] that assessed metastases from renal cell carcinoma in various organs reported on complete metastasectomy versus no metastasectomy, incomplete metastasectomy, or both (table 2) . However, in one study, 32 complete resection was achieved in only 45% of the metastasectomy group, which was compared with patients with no metastasectomy. No other focal treatment modalities were applied. In six of the eight studies, 12,24,26,27,30,32 a signifi cantly longer median overall survival or cancer-specifi c survival was reported after complete metastasectomy compared with incomplete or no metastasectomy (median of medians overall survival or cancer-specifi c survival 40·8 months, IQR 31·6-48·0), or both (14·8 months, 13·3-21·0). Of the two remaining studies, in one 29 there was no signifi cant diff erence in cancer-specifi c survival between complete metastasectomy and no metastasectomy (58 vs 50 months; p=0·223); however, only 18 and 16 patients were assessed in the respective study groups. In the other study 31 there was a numerically longer median overall survival for the metastasectomy group (30 vs 12 months), but the p value was not provided. A forest plot of hazard ratios for overall survival or cancer-specifi c survival in studies in which incomplete or no metastasectomy was compared with complete metastasectomy for metastatic renal cell carcinoma to various organs shows improved overall survival and cancer-specifi c survival for complete metastasectomy (fi gure 2).
Regarding metastasectomy in specifi c organs, three studies assessed metastases to lung, 23 liver, 25 and pancreas (table 2) . 28 In the lung study, 23 there was signifi cantly higher median overall survival after metastasectomy compared with both targeted treatment and immunotherapy (36·3 vs 30·4 and 18·0 months, respectively, p<0·05). In the liver study, 25 median overall survival was signifi cantly higher for metastasectomy compared with no metastasectomy (142 months [95% CI 115-169] vs 27 months ; p=0·003). In the pancreas study, 28 5-year overall survival was numerically higher for metastasectomy compared with no metastasectomy (88% vs 47%). Median overall survival was signifi cantly longer for metastasectomy (p=0·0263; table 2).
Three studies on local treatments for bone metastases were identifi ed (table 2). In one study, 33 single-dose image-guided radiotherapy (IGRT) was compared with hypofractionated IGRT in patients with bone metastases in various locations. Patients treated with single-dose IGRT (≥24 Gy) had a signifi cantly better 3-year actuarial local progression-free survival than those treated with hypofractionated IGRT (88% vs 17%; p=0·001), which was also shown with a Cox regression analysis (p=0·008). In another study, 35 metastasectomy with curettage and local stabilisation was compared with no surgical treatment of solitary bone metastases in various locations. A signifi cantly higher proportion of patients who underwent surgical intervention achieved 5-year cancerspecifi c survival compared with those with no intervention (36% vs 8%; p=0·0066). Findings from a multivariate analysis of cancer-specifi c survival, adjusting for previous nephrectomy, sex, and age, still favoured metastasectomy with curettage and intramedullary stabilisation compared with no surgical treatment (p=0·018). A third study 34 compared the effi cacy and durability of pain relief between single-dose SBRT and CRT in patients with bone metastases to the spinal column (C1 sacrum); no signifi cant diff erence between pain objective responses (p=0·67), time to pain relief (p=0·29), or duration of pain relief (p=0·095) was found (table 2).
Local therapies for brain metastases
Two studies on brain metastases from renal cell carcinoma were included (table 2). One study 36 compared SRS, WBRT, and the combination of both SRS and WBRT. All patients in the WBRT and combination groups had at least two brain metastases, whereas such patients accounted for 17·6% of the SRS group. Each group was further subdivided into recursive partitioning analysis (RPA), a statistical method for undertaking multivariate analysis, based on a decision tree with dichotomous variables classes I-III (I=favourable, II=moderate, and III=poor patient status). A signifi cant Review improvement in 2-year intracerebral control was found when adding WBRT to SRS compared with SRS alone (p=0·032), but no such diff erence was noted for 2-year overall survival (p=0·703); both were superior to WBRT alone in the general study population (all p<0·001) and in the RPA subgroup analyses (all p<0·001). In a subgroup analysis of RPA class I, the comparison of SRS with SRS plus WBRT revealed signifi cantly better 2-year overall survival and intracerebral control for the combination group (p<0·001 for both). The other study 37 compared fractionated stereotactic radiotherapy (FSRT) with metastasectomy plus CRT, or CRT alone. Only six (55%) patients after metastasectomy plus CRT and four patients (33%) after CRT were followed up with imaging. Several of the patients in all groups underwent alternative surgical and non-surgical treatments after initial treatment. Survival at 1, 2, and 3 years were 90%, 54%, and 41% for FSRT, 64%, 27%, and 9% for metastasectomy plus CRT, and 25%, 17% and 8% for CRT, respectively. No p value was reported for survival. FSRT did not have a signifi cantly better 2-year local control compared with metastasectomy plus CRT (p=0·61); whether FSRT gave signifi cantly better 2-year local control than CRT alone was not reported. Figure 3 summarises the risk of bias and confounding for all included studies. All studies were retrospective and non-randomised, leading to the high risk of bias associated with non-randomisation, patient attrition, and selective reporting. With the exception of one study, 12 all studies were substantially underpowered. Regarding confounding, about half of studies reported adequate data on age and sex. Systemic treatment type and the frequency of their use were heterogeneous. Although performance status was included in the baseline characteristics in most studies, there was heterogeneity in performance status classifi cation. There was a moderate-to-high risk of confounding regarding previous treatment, tumour histology, grade, and size or volume of metastases, especially in studies on local treatments of bone and brain metastases. [33] [34] [35] [36] [37] Regarding diff erent sites treated in the same study, there was generally a moderate-to-high risk of confounding, especially for studies pertaining to treatment of metastases at various sites, 12, 27, [30] [31] [32] because it was often unclear if these confounders were adjusted. Evidence quality was not assessed by GRADE because of the nature of the included studies (ie, retrospective comparative studies), and the high risk of bias across the studies.
Risk of bias and confounding

Discussion
The results of this systematic review suggest a survival benefi t with complete metastasectomy versus either incomplete or no metastasectomy for renal cell carcinoma metastases to parenchymal organs. There was also some evidence in favour of local treatment in terms of symptom control, such as pain relief in patients with bone metastases. The great variation in type and distribution of systemic treatment, and its response being reported in only a subset of studies, prevents any conclusion on the role and eff ect of targeted treatment in the setting of complete metastasectomy. However, in a non-comparative report, 38 most patients who had a complete response after a combination of targeted treatment and local treatment stopped systemic treatment. After a median follow-up of 10·7 months (range 0·3-54·0), 48% of patients had still not experienced disease progression; these data suggest that local treatment might have a role in delaying return to systemic treatment and associated toxicity.
The main strength of this Review is its robust methodology, which adheres to strict criteria that are rigorous, transparent, and reproducible. We have described the best available contemporary evidence base, from which 12 Amiraliev et al (2012) 23 Brinkmann et al (2007) 29 Eggener et al (2008) 27 Fokas et al (2010) 36 Fuchs et al (2005) 35 Hunter et al (2012) 34 Ikushima et al (2000) 37 Kwak et al (2007) 30 Lee et al (2006) 32 Pretalia et al (2010) 24 Russo et al (2007) 31 Staehler et al (2009) 26 Staehler et al (2010) 25 Zelefsky et al (2012) 33 Zerbi et al (2008) Review some conclusions can be made, and identifi ed knowledge gaps that can only be addressed through well-designed, prospective comparative studies. However, there are several limitations. All included studies were retrospective comparative studies, involving small numbers of patients; there were no randomised controlled trials or prospective nonrandomised comparative studies. There were generally high risks of bias across all included studies and across most domains, including a substantial risk of confounding. As a result, only a narrative synthesis of the evidence was presented; a meta-analysis was not possible because of the aforementioned limitations. Additionally, the search was limited to studies published from 2000 onwards; earlier publications might have been missed, although a scoping exercise of the available published work before 2000 did not reveal any randomised controlled trials. The generally poor quality of the evidence base imply that there is signifi cant uncertainty regarding our fi ndings, and, therefore, caution is needed in their interpretation. For instance, we cannot rule out that the reported benefi t is largely due to an indication bias on the basis of diff erences in tumour aggressiveness. Potentially, patients with oligometastasis and long metachronous intervals are more likely to be candidates for metastasectomy, whereas those with a high-volume metastasis, rapid progression, and reduced performance status often do not undergo resection. Several non-comparative studies suggest that the disease dynamic might be more important than any intervention. Low tumour grade 39 and long metachronous intervals with repeat resection 40 are associated with long survival. No reliable data exist on the proportion of patients with metastatic renal cell carcinoma who would be eligible for local treatment of their metastases. At diagnosis, 57-65% of patients with metastatic renal cell carcinoma have single sites; the percentage of patients with single sites increases with age. 10 Estimates suggest that 25% of patients with metachronous metastasis might be candidates for local treatment. 12 For synchronous metastatic disease, this proportion may be less than 10%. 41 The investigators of most studies identifi ed in this systematic review acknowledge that patient selection for local treatment of metastases is complex because of the heterogeneous course of metastatic renal cell carcinoma, surgical resectability, and anatomical access.
There is general consensus that several clinical and pathological factors, such as performance status, diseasefree interval, burden and site of metastases, histological subtype, and Fuhrman grade aff ect the prognosis and management of metastatic renal cell carcinoma to a large extent. 42 Most of the data on metastasectomy exist for patients with clear-cell renal cell carcinoma; little is known for other subtypes such as papillary renal cell carcinoma. 43 Accurate information on prognosis is of utmost importance for treatment decisions. The Memorial Sloan Kettering Cancer Centre (MSKCC) risk score is one of the most commonly used prognostic models and establishes which patients have favourable, intermediate, and poor risks using Karnofsky performance status, the time from diagnosis to treatment, and serum haemoglobin, calcium, and lactate dehydrogenase concentrations.
44 Surprisingly, we identifi ed only two studies that reported the MSKCC score. 25, 27 For patients receiving targeted treatment, the MSKCC score and the validated Database Consortium model share concordance indices of 0·66-0·65 to assess prognosis. 8, 45, 46 In one of the studies included in the systematic review, a more favourable risk category and metastasectomy were each independently associated with better survival. 27 However, this may be because, with a median survival of 6 months for poor-risk patients, these patients do not live long enough to derive benefi t from metastasectomy. Other more site-specifi c clinical factors that might have prognostic value for local treatment of metastases are recognised, and were partly discussed in the studies included in the systematic review.
Most data exist for lung metastases, which are the most common metastases from renal cell carcinoma. Large, non-comparative case series not included in the systematic review reported 5-year survival of 37-54% for completely resected solitary or oligometastatic pulmonary metastases. [47] [48] [49] [50] [51] [52] [53] Multivariate analyses consistently identifi ed a pattern of prognostic factors (panel). Having a higher number of removed pulmonary metastases, 12, 51, 54 concomitant mediastinal nodal metastasis, 47, [51] [52] [53] or incomplete resection 12, 48, [51] [52] [53] [54] was associated with poorer 5-year survival of 0-24·4%. Additionally, a short diseasefree interval after nephrectomy or synchronous metastasis was associated with a poor outcome, 48, 51, 52, 54 as was size of lung metastases. 47, 52, 55 A lung-specifi c prognostic score including these factors has been developed from 200 consecutive patients with pulmonary metastases; this score needs external validation. 56 Interpretation of the identifi ed studies for bone and brain metastases that assessed radiotherapy or compared radiotherapy to surgery is problematic. During the long study periods of 6-15 years represented by the included studies, substantial advances were made in radiotherapy, including changes in dosage and modalities. Additionally, location, size, and soft-tissue involvement of metastases varied substantially between studies, and were inconsistently reported, which prevented a direct comparison of results. Although fi ndings from this systematic review suggest prolonged disease-free survival after SBRT or metastasectomy of single and multiple bone metastases, no recommendations can be made as to the best treatment modality. However, fi ndings from a randomised controlled trial in patients with bone metastasis from various cancers, including renal cell carcinoma, showed that immediate decompressive surgery and postoperative radiotherapy is superior to radiotherapy alone for patients with spinal cord compression. 57 Findings from a further small non-comparative study suggested Review SRS reduced progression and pain in patients with renal cell carcinoma spinal lesions. 58 In addition to general prognostic factors, peripheral location of bone metastases is a favourable factor. 12, [59] [60] [61] [62] Only two studies were identifi ed that compared diff erent radiotherapy modalities, including in combination with surgery, for brain metastases from renal cell carcinoma. Thus, recommendation of a specifi c treatment modality is not possible. However, fi ndings from additional studies on non-renal cell carcinoma brain metastases suggest a prognostic score-related approach. With SRS, craniotomy is now not frequently used except for brain metastases larger than 3 cm in size, and rapidly symptomatic lesions with midline shift. 63, 64 Brain metastases from renal cell carcinoma were mostly assessed collectively with cerebral lesions from other malignancies. Recommendations for radiotherapy follow the Radiation Therapy Oncology Group RPA developed from brain metastases irrespective of the primary tumour site (RPA class I: Karnofsky performance status ≥70, age <65 years, primary tumour controlled, no extracranial sites; class II: Karnofsky performance status ≥70 with absence of at least one of the other factors; class III: Karnofsky performance status <70). 65 About three-quarters of patients belong to RPA class II. 63, 66 In a retrospective non-comparative study, 85 patients with renal cell carcinoma with brain metastases who underwent SRS were assessed. 63 Median metastatic volume was 1·2 cm (range 0·1-14·2) and 65% of patients had multiple cerebral metastases. After SRS, median overall survival was 11 months with 94% of patients achieving local control. Most patients (78%) died of extracranial progression. Median overall survival was 24·2 months for RPA class I, 9·2 months for class II, and 7·5 months for class III. In a study of 4295 patients with brain metastases from renal cell carcinoma, Karnofsky performance status and number of brain metastases were identifi ed as signifi cant prognostic factors. 67 Patients with a Karnofsky performance status of 90-100 and one brain lesion had a median overall survival of 14·8 months (95% CI 12·9-17·1) versus 3·3 months (3·0-3·8) for those with a Karnofsky performance status less than 70 and more than three metastases. Present data suggest that WBRT is adequate for patients with poor performance who need palliative treatment for multiple lesions. SRS can provide eff ective local control comparable to surgery, even for multiple and recurrent metastases, and is recommended for patients with RPA classes I and II. 68 For liver and pancreatic metastases, a potential benefi t needs to be balanced against morbidity and mortality of local treatment. In the study included in this systematic review, liver metastasectomy was associated with signifi cant morbidity in 20·1% of patients, 25 with no benefi t for those with high-grade renal cell carcinoma and synchronous metastases. By contrast, a non-comparative retrospective analysis of 43 patients reported low morbidity and mortality, resulting in a 3-year overall survival of 62·1% and a median recurrence-free survival of 15·5 months. 69 Additionally, ablative techniques and SRS have resulted in eff ective local control of small liver metastases. [70] [71] [72] Cumulative data suggest that pancreatic metastasectomy might be benefi cial in patients with good performance status and one metastatic site. 73 However, 2·8% inhospital mortality after extensive surgery, done as pancreaticoduodenectomy in 35·8% of patients and total pancreatectomy in 19·9% of patients, suggests that morbidity and mortality might outweigh the potential benefi t. In view of the overall low quality of the data, and the substantial surgical morbidity, patients with a short interval to pancreatic metastasis after nephrectomy may be best treated with systemic therapy.
Despite lymph nodes being the third metastatic site in 21·8% of patients, 10 we identifi ed few studies reporting Review on only subgroups of patients who underwent nodal metastasectomy, compared with either no or incomplete resection. Isolated metachronous nodal metastases are rare and most patients harbour additional extensive metastatic disease at multiple sites, 74 precluding complete metastasectomy, which might explain the low number of comparative retrospective studies retrieved.
In conclusion, to the best of our knowledge, this is the fi rst systematic review to identify the evidence base regarding the role of local treatment of metastases from renal cell carcinoma. The results consistently point towards a benefi t of complete metastasectomy in terms of overall survival and cancer-specifi c survival. With the exception of brain and possibly bone metastases, metastasectomy remains by default the most appropriate local treatment for most sites. There is also some evidence for local control benefi ts such as pain relief for bone metastases. Because of the poor quality of included studies, whether the reported survival benefi t is a consequence of local treatment, or a selection bias of those patients whose tumour biology allowed them to proceed to metastasectomy, or both, remains unresolved. Future prospective studies, preferably with randomised design and larger populations, are needed to increase the quality of evidence regarding local treatment of metastases from renal cell carcinoma. Finally, from a clinical perspective, the possible survival and symptom control benefi ts in patients with metastatic renal cell carcinoma who are eligible for local treatment should be discussed in multidisciplinary boards to tailor treatments individually. Despite prognostic factors consistently being associated with a favourable outcome after metastasectomy, no general treatment guideline can be given, because of the large uncertainties that exist in the evidence base. Careful patient selection is of paramount importance, and the decision to resect metastases has to be taken for each site, and on a caseby-case basis. Performance status, risk profi les, patient preference, and alternative techniques to achieve local control, such as SRS or ablation, must be considered. There might also be a role for local treatment of metastases in terms of delaying systemic treatment and associated toxicity.
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